Accelerating Monoclonal Antibody Screening with Automation in Cell Line Development
Monoclonal antibodies (mAbs) are integral to current drug development pipelines. Identifying high-yielding and high-quality mAb-producing clones is now the end goal of cell line development (CLD) in biotherapeutic production processes. However current CLD workflows are complex, challenging, and resource-intensive for manufacturers.
A bottleneck in antibody screening
During CLD, too many candidate cell lines are produced to screen manually. preliminary collection typically relies on helpful but hands-on analytics, such as protein quantification assays, and rapid binding assays, which can take weeks or even months, slowing down the CLD workflow. Fortunately, there are now tools that can significantly accelerate CLD by allowing manufacturers to obtain highly detailed, high-throughput and comprehensive data in line with other analytical assays.
Enter automation
Automation can eliminate many initial antibody screening steps. A chip-based, integrated solution can offer up front access to multidimensional data within minutes instead of months, enabling faster, more accurate decision-making. For example, the SCIEX Intabio ZT System is an analytical solution that SCIEX ZenoTOF 7600 high-resolution mass spectrometer allows rapid identification of mAb variants. The combination of isoelectric focusing and mass spectrometry allows for identification of proteoforms within minutes¹ and glycosylation variants within an hour². Sample prep automation has made the SCIEX Intabio ZT System streamlined and highly reproducible³, assuring the reliability of results for analysis.
The future of drug development
Do you find that screening for mAb candidates is a bottleneck in your CLD workflow? Automation solutions can significantly simplify your analysis. Contact an expert at the Life Sciences companies of Danaher Corporation to learn more about discovering and developing your next breakthrough medicine.